Comparative Pharmacogenomics Laboratory, Program in Individualized Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington (S.E.M., T.E.P.J., Z.Z., M.H.C.); and Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (J.S., H.-J.Z.)
Comparative Pharmacogenomics Laboratory, Program in Individualized Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington (S.E.M., T.E.P.J., Z.Z., M.H.C.); and Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (J.S., H.-J.Z.).
Drug Metab Dispos. 2019 Nov;47(11):1314-1324. doi: 10.1124/dmd.119.088070. Epub 2019 Aug 19.
Dogs are commonly used in human and veterinary pharmaceutical development. Physiologically based pharmacokinetic modeling using recombinant cytochrome P450 (CYP) enzymes requires accurate estimates of CYP abundance, particularly in liver. However, such estimates are currently available for only seven CYPs, which were determined in a limited number of livers from one dog breed (beagle). In this study, we used a label-free shotgun proteomics method to quantitate 11 CYPs (including four CYPs not previously measured), cytochrome P450 oxidoreductase, and cytochrome b5 in liver microsomes from 59 dogs representing four different breeds and mixed-breed dogs. Validation included showing correlation with CYP marker activities, immunoquantified protein, as well as CYP1A2 and CYP2C41 null allele genotypes. Abundance values largely agreed with those previously published. Average CYP abundance was highest (>120 pmol/mg protein) for CYP2D15 and CYP3A12; intermediate (40-89 pmol/mg) for CYP1A2, CYP2B11, CYP2E1, and CYP2C21; and lowest (<12 pmol/mg) for CYP2A13, CYP2A25, CYP2C41, CYP3A26, and CYP1A1. The CYP2C41 gene was detected in 12 of 58 (21%) livers. CYP2C41 protein abundance averaged 8.2 pmol/mg in those livers, and was highest (19 pmol/mg) in the only liver with two CYP2C41 gene copies. CYP1A2 protein was not detected in the only liver homozygous for the CYP1A2 stop codon mutation. Large breed-associated differences were observed for CYP2B11 ( < 0.0001; ANOVA) but not for other CYPs. Research hounds and Beagles had the highest CYP2B11 abundance; mixed-breed dogs and Chihuahua were intermediate; whereas greyhounds had the lowest abundance. These results provide the most comprehensive estimates to date of CYP abundance and variability in canine liver. SIGNIFICANCE STATEMENT: This work provides the most comprehensive quantitative analysis to date of the drug-metabolizing cytochrome P450 proteome in dogs that will serve as a valuable reference for physiologically based scaling and modeling used in drug development and research. This study also revealed high interindividual variation and dog breed-associated differences in drug-metabolizing cytochrome P450 expression that may be important for predicting drug disposition variability among a genetically diverse canine population.
狗通常被用于人类和兽医制药的开发。使用重组细胞色素 P450(CYP)酶进行基于生理学的药代动力学建模需要对 CYP 丰度进行准确估计,特别是在肝脏中。然而,目前只有七种 CYP 可以进行这种估计,这些 CYP 是在一个犬种(比格犬)的有限数量的肝脏中确定的。在这项研究中,我们使用无标签的鸟枪法蛋白质组学方法来定量检测 59 只狗的肝脏微粒体中的 11 种 CYP(包括以前未测量的四种 CYP)、细胞色素 P450 氧化还原酶和细胞色素 b5。验证包括与 CYP 标记活性、免疫定量蛋白以及 CYP1A2 和 CYP2C41 缺失等位基因基因型的相关性。丰度值与以前发表的值基本一致。CYP2D15 和 CYP3A12 的 CYP 丰度最高(>120 pmol/mg 蛋白);CYP1A2、CYP2B11、CYP2E1 和 CYP2C21 的 CYP 丰度为中等(40-89 pmol/mg);CYP2A13、CYP2A25、CYP2C41、CYP3A26 和 CYP1A1 的 CYP 丰度最低(<12 pmol/mg)。CYP2C41 基因在 58 只肝脏中的 12 只(21%)中被检测到。在这些肝脏中,CYP2C41 蛋白的丰度平均为 8.2 pmol/mg,在唯一具有两个 CYP2C41 基因拷贝的肝脏中最高(19 pmol/mg)。在唯一纯合 CYP1A2 终止密码子突变的肝脏中未检测到 CYP1A2 蛋白。观察到 CYP2B11(<0.0001;ANOVA)存在大型犬种相关差异,但其他 CYP 则不存在。研究猎犬和比格犬的 CYP2B11 丰度最高;混合犬种和吉娃娃犬的 CYP2B11 丰度中等;而灵缇犬的 CYP2B11 丰度最低。这些结果提供了迄今为止犬科肝脏中细胞色素 P450 含量和可变性的最全面估计,将为药物开发和研究中使用的基于生理学的缩放和建模提供有价值的参考。本研究还揭示了药物代谢细胞色素 P450 表达在个体间存在高度的变异性和犬种相关差异,这对于预测具有遗传多样性的犬科动物群体中药物处置的变异性可能很重要。